CIK 0001398733
- Non-accelerated filer
- Smaller reporting company
Aquestive Therapeutics, Inc.
Sign in to watch- Ticker
- AQST
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 208623253
- Phone
- +1 908-941-1900
- Business address
- 184 LIBERTY CORNER ROAD, SUITE 305, WARREN, NJ
- Former names
- MonoSol Rx, Inc.
- 4 Open-market sale Chief People Officer sold 29,814 shares at $4.17 ($124,414)
- 4 Open-market sale President and CEO sold 180,677 shares at $4.17 ($753,965)
- 4 Open-market sale Chief Legal Officer sold 40,102 shares at $4.17 ($167,346)
- 4 Open-market sale SVP, Regulatory Affairs sold 25,311 shares at $4.17 ($105,623)
- 4 Open-market sale Chief Financial Officer sold 58,254 shares at $4.17 ($243,094)
- 4 Open-market sale Chief Commercial Officer sold 15,741 shares at $4.17 ($65,687)
- 4 Open-market sale Chief Operating Officer sold 45,791 shares at $4.17 ($191,086)
- 4 Grant or award Chief Development Officer acquired 50,000 shares (grant or award)
- 4 Grant or award Chief Medical Officer acquired 75,000 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4 Grant or award Chief People Officer acquired 20,000 shares (grant or award)
- 4 Shares withheld for taxes SVP, Regulatory Affairs gave up 2,083 shares (to pay taxes)
- 4 Grant or award Chief Development Officer acquired 50,000 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4 Planned sale Chief Operating Officer sold 67,575 shares at $7.01 ($473,701)
- 4 Planned sale Chief Medical Officer sold 20,272 shares at $7.00 ($141,904)
- 4 Planned sale See Remarks sold 10,000 shares at $7.00 ($70,000)
- 4 Planned sale President and CEO sold 91,343 shares at $6.03 ($551,191)
- 4 Planned sale See Remarks sold 10,000 shares at $6.30 ($63,000)
- 4 Planned sale President and CEO sold 400 shares at $6.00 ($2,400)
Page 3 of 17 · 326 filings